Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/4/2007 2:28:13 AM
	Read Replies (1) of 933

Wachovia Starts Kosan Biosciences (KOSN) at Market Perform 12-03-2007 05:42:26 PM Wachovia initiates coverage on Kosan Biosciences Inc. (Nasdaq: KOSN) with a Market Perform rating and $5-$6 valuation range. The firm said they believe the stock will trade-in with the market near term, saying meaningful catalyst will not occur until H2:08E. The firm see limited risks in tanespimycin's Phase III program, but says potential in Multiple Myeloma will be hindered by the fact that it is being developed in combination with Velcade.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next